In­cyte CEO Hervé Hop­penot sees block­buster po­ten­tial for Opzelu­ra, even as an­a­lysts shake their heads in doubt

De­spite In­cyte’s top­i­cal atopic der­mati­tis drug get­ting slapped with a black box warn­ing — and com­ing in be­low Wall Street’s ex­pec­ta­tions for its first quar­ter on the mar­ket — CEO Hervé Hop­penot called the launch “very suc­cess­ful,” peg­ging a $1.5 bil­lion peak sales es­ti­mate in the US.

How­ev­er, an­a­lysts can’t seem to agree on just how re­al­is­tic that is giv­en chal­lenges with re­im­burse­ment — and in­vestors seem to be erring on the side of cau­tion. In­cyte’s stock $IN­CY was down 2.6% on Wednes­day morn­ing, pric­ing in at $68.25 per share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER